Doubling back on centromere 17 in early breast cancer
- PMID: 20202603
- DOI: 10.1016/S1470-2045(10)70020-6
Doubling back on centromere 17 in early breast cancer
Comment on
-
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1. Epub 2010 Jan 13. Lancet Oncol. 2010. PMID: 20079691
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
